Schellenberg Wittmer advised Emerald Technology Ventures, a venture capital firm focusing on sustainable industrial innovation, in obtaining its FINMA license as asset manager of collective assets with the Swiss Financial Supervisory Authority (FINMA). Emerald Technology
Wenger Vieli advised Progile, an AI company based in Zurich, on all Swiss legal matters concerning their recent funding round. This secured funding of CHF 1.3 million, which will serve to increase the development and distribution
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
Roche Finance Europe issued EUR 1.5 billion bonds guaranteed by Roche Holding, advised by Homburger. Advestra advised BNP Paribas and the banking syndicate on the placement. Banco Santander, BNP Paribas and UniCredit Bank acted as joint
Advestra advised Cactus life sciences, a global scientific communications agency that works with blue chip pharma and biotechnology companies, on nspm and eluSCIdate’
Walder Wyss, together with CastaldiPartners, advised Provost on its acquisition of Mino & Lorenzini. Walder Wyss’ team comprised corporate and M&A partner Luc Defferrard (pictured) and corporate / M&A associate Ken Savioz.
Lenz & Staehelin advised Vaudoise Assurances on all legal and tax aspects of the acquisition of 100% of the share capital of Prevanto. Walder Wyss advised the sellers on all legal aspects of the transaction. Active
Bär & Karrer and Willkie Farr & Gallagher advised PAI Partners (PAI) on the acquisition of Vamed Group’s rehabilitation business (VAMED) from Fresenius, advised by NKF and Latham & Watkins. PAI will become
Walder Wyss advised the funds managed by Pharmakon Advisors, an investor in non-dilutive debt for the life sciences industry and investment manager of the BioPharma credit funds. Banking and finance counsel Tervel Stoyanov (pictured left)
Advestra advised UBS on EUR 300 million rights offering by Swiss Steel. The transaction consisted in an offering of subscription rights and a placement of shares on which rights
